Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.46 |
| ▸ | BCHE | P06276 | 9/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.40 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021219 | 1.00 | ACHE (0.46) | ACHEBCHEGRIN1GRIN2AHSD17B10 | |
| SCHEMBL22020129 | 0.82 | ACHE (0.54) | ACHEBCHEGRIN1GRIN2AHSD17B10 | |
| SCHEMBL30162655 | 0.82 | ACHE (0.54) | ACHEBCHEGRIN1GRIN2AHSD17B10 | |
| SCHEMBL21963395 | 0.78 | KDM4E (0.52) | ACHEBCHEGRIN1GRIN2AKDM4E | |
| SCHEMBL21963085 | 0.78 | ACHE (0.42) | ACHEBCHEGRIN1GRIN2AKDM4E | |
| SCHEMBL30162742 | 0.77 | ACHE (0.47) | ACHEBCHEGRIN1GRIN2AALDH1A1 | |
| SCHEMBL22021220 | 0.77 | ACHE (0.47) | ACHEBCHEGRIN1GRIN2AALDH1A1 | |
| SCHEMBL30162468 | 0.73 | MAPT (0.37) | BCHETSHRALDH1A1KDM4EAPP | |
| SCHEMBL21963214 | 0.70 | ACHE (0.52) | ACHEBCHEGRIN1GRIN2AHSD17B10 | |
| SCHEMBL30162391 | 0.70 | ACHE (0.52) | ACHEBCHEGRIN1GRIN2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ACHE 4177/4885BCHE 4143/4885GRIN1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.